Long‐Acting Technologies to Prevent HIV: Why Is the Asia‐Pacific Being Left Behind?

Documenti analoghi

• From Kigali to Rio: advancing an evidence‐based and equitable HIV response
  di: Beatriz Grinsztejn, et al.
  Pubblicazione: (2025)
• Effectiveness and Persistence of Long‐Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort
  di: Jara Llenas‐García, et al.
  Pubblicazione: (2026)
• A roadmap to scale up person‐centred care in the HIV response: recommendations from a global consensus‐building process
  di: Lina Golob, et al.
  Pubblicazione: (2025)
• Differences in clinical characteristics between adolescents and young adults with perinatally and sexually acquired HIV in the Asia‐Pacific region
  di: Phatharajit Phatharodom, et al.
  Pubblicazione: (2025)
• Exploring potential drug−drug interactions between masculinizing hormone therapy and oral pre‐exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open‐label pharmacokinetic study in Thailand
  di: Akarin Hiransuthikul, et al.
  Pubblicazione: (2025)